Impedimed Ltd (OTCPK:IPDQF)
$ 0.048 0 (0%) Market Cap: 70.20 Mil Enterprise Value: 54.36 Mil PE Ratio: 0 PB Ratio: 2.40 GF Score: 0/100

Q2 2022 ImpediMed Ltd Activities Report Call Transcript

Jan 31, 2022 / 12:30AM GMT
Release Date Price: $0.12354 (+7.43%)
Operator

Thank you for standing by, and welcome to the ImpediMed Limited Quarterly Results and Investor Conference Call. (Operator Instructions)

I would now like to hand the conference over to Mr. Richard Carreon, Managing Director and CEO. Please go ahead.

Richard Carreon
ImpediMed Limited - MD, CEO, President & Executive Director

Thanks, Kelly. Welcome, everyone, and thank you for joining us today. We're hosting this conference call to discuss our 4C for the financial quarter ending 31 December 2021. Joining us on the call today is Tim Cruickshank, our Chief Financial Officer; and Mike Bassett, our Senior Vice President of Corporate and Strategic Development.

I'll be referencing the 4C and speaking from the quarterly activity report we lodged this morning Australian time. This presentation is a summary of the more detailed 4C. After our remarks, we'll be taking questions.

Let me first start off by providing an update on the publication of the PREVENT trial. The principal investigator, Dr. Sheila Ridner, received notification late last

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot